Literature DB >> 2072295

Cationization of immunoglobulin G results in enhanced organ uptake of the protein after intravenous administration in rats and primate.

D Triguero1, J L Buciak, W M Pardridge.   

Abstract

Cationization of proteins in general enhances the cellular uptake of these macromolecules, and cationized antibodies are known to retain antigen binding properties. Therefore, cationized antibodies may be therapeutic and allow for "intracellular immunization." The present studies test the hypothesis that the tissue uptake of cationized immunoglobulin G (IgG) after intravenous administration may be greatly increased relative to the uptake of native proteins. The pharmacokinetics of cationized immunoglobulin G clearance from blood, and the volume of distribution of the cationized or native protein (albumin, IgG) for 10 organs was measured both in anesthetized rats and in an anesthetized adult Macaca irus cynomologous monkey. Initial studies on brain showed that serum factors inhibited uptake of 125I-cationized IgG, but not 3H-cationized IgG. The blood-brain barrier permeability surface area product for 3H-cationized IgG was 0.57 +/- 0.04 microliters min-1 g-1. The ratio of the volume of distribution of the 3-H-cationized IgG compared to 3H-labeled native albumin ranged from 0.9 (testis) to 15.7 (spleen) in the rat at 3 hr after injection, and a similarly enhanced organ uptake was observed in the primate. In conclusion, these studies demonstrate that cationization of immunoglobulin greatly increases organ uptake of the plasma protein compared to native immunoglobulins, and suggest that cationization of monoclonal antibodies may represent a potential new strategy for enhancing the intracellular delivery of these proteins.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2072295

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  New technologies for drug delivery across the blood brain barrier.

Authors:  A V Kabanov; E V Batrakova
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

2.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

Review 3.  Targeting the brain: rationalizing the novel methods of drug delivery to the central nervous system.

Authors:  Shailendra Joshi; Eugene Ornstein; Jeffrey N Bruce
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

Review 4.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

Review 5.  Passage of intravenous immunoglobulin and interaction with the CNS.

Authors:  U Wurster; J Haas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

6.  Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier.

Authors:  Isabelle St-Amour; Isabelle Paré; Wael Alata; Katherine Coulombe; Cassandra Ringuette-Goulet; Janelle Drouin-Ouellet; Milène Vandal; Denis Soulet; Renée Bazin; Frédéric Calon
Journal:  J Cereb Blood Flow Metab       Date:  2013-09-18       Impact factor: 6.200

7.  Species and immunoglobulin preparation related effects on the biodistribution of technetium-99m-labelled immunoglobulin G in a baboon model.

Authors:  W K Louw; I C Dormehl; N Hugo; I F Redelinghuys
Journal:  Eur J Nucl Med       Date:  1993-02

8.  Biodistribution of charged F(ab')2 photoimmunoconjugates in a xenograft model of ovarian cancer.

Authors:  L R Duska; M R Hamblin; M P Bamberg; T Hasan
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.